文摘
A novel bifunctional maleimido CHX-A″ DTPA chelator <strong>5strong> was developed and conjugated to the monoclonal antibody trastuzumab (Herceptin) and subsequently radiolabeled with <sup>111sup>In. The resulting <sup>111sup>In labeled immunoconjugate <strong>2strong> was demonstrated to bind to SKOV-3 ovarian cancer cells comparably to an isothiocyanato CHX-A″ DTPA modified native trastuzumab, <strong>1strong>. Through efficient thiol-maleimide chemistry, antibodies, peptides or other targeting vectors can now be modified with an established radioactive metal chelating agent CHX-A″ DTPA for imaging and/or therapies of cancer.